Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5150-5154

  Espinel Ingroff, A ^a   Cuenca Estrella, M ^b   Fothergill, A ^c   Fuller, J ^d   Ghannoum, M ^e   Johnson, E ^f   Pelaez, T ^g   Pfaller, M A ^h   Turnidge, J ⁱ  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f NHS BLOOD AND TRANSPLANT   (United Kingdom)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h UNIVERSITY OF IOWA   (United States)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; BROTH DILUTION; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

AMPHOTERICIN B; ASPERGILLUS; MICROBIAL SENSITIVITY TESTS;

EID: 80054696205     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00686-11     Document Type: Article

References (35)

1. Alcazar-Fuoli, L., et al. 2008. Aspergillus section fumugati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52:1244-1251. (Pubitemid 351521983)
2. Alcazar-Fuoli, L., et al. 2009. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob. Agents Chemother. 53:4514-4517.
3. Baddley, J. W., et al. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network. J. Clin. Microbiol. 47:3271-3275.
4. Balajee, S. A., J. L. Gribskov, E. Hanley, D. Nickle, and K. A. Marr. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4:625-632. (Pubitemid 40383765)
5. Barnes, P. D., and K. A. Marr. 2007. Risk, diagnosis and outcome of invasive fungal infections in haematopoietic stem cell transplant recipients. Br. J. Haematol. 139:519-531. (Pubitemid 350043811)
6. Blum, G., et al. 2008. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52:1553-1555. (Pubitemid 351522034)
7. Chryssanthou, E., and M. Cuenca-Estrella. 2006. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin. Microbiol. Infect. 12:901-914.
8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2010. Method for antifungal disk diffusion susceptibility testing of non-dermatophyte fungi; approved standard. CLSI document M51-A. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Dalhoff, A., P. G. Ambrose, and J. W. Mouton. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
11. Erjavec, Z., H. Kluin-Nelemans, and P. E. Verweij. 2009. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin. Microbiol. Infect. 15:625-633.
12. Espinel-Ingroff, A., et al. 2001. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp. NCCLS Collaborative Evaluation. Antimicrob. Agents Chemother. 45:1828-1835. (Pubitemid 32466356)
13. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by the NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136. (Pubitemid 38724618)
14. Espinel-Ingroff, A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2). J. Clin. Microbiol. 48:3251-3257.
15. Espinel-Ingroff, A., et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:2855-2859.
16. Gomez-Lopez, A., et al. 2005. Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. Clin. Microbiol. 43:1251-1255. (Pubitemid 40364947)
17. Lass-Florl, C., et al. 2009. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:794-795.
18. Lestner, J. M., et al. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54:3432-3441.
19. Messer, S. A., R. N. Jones, and T. R. Fritsche. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J. Clin. Microbiol. 44:1782-1787. (Pubitemid 43726269)
20. Nivoix, Y., et al. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47:1176-1184.
21. Panackal, A. A., A. Imhof, E. W. Hanley, and K. A. Marr. 2006. Aspergillus ustus infections among transplant recipients. Emerg. Infect. Dis. 12:403-408.
22. Pfaller, M. A., et al. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
23. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
24. Richardson, M., and C. Lass-Florl. 2008. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. 14:5-24. (Pubitemid 351593913)
25. Rodriguez-Tudela, J. L., et al. 2008. Epidemiological cutoffs and crossresistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
26. Seo, K., H. Akiyoshi, and Y. Ohnishi. 1999. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol. Immunol. 43:1017-1025.
27. Shao, P.-L., L.-M. Huang, and P.-R. Hsueh. 2007. Recent advances and challenges in the treatment of invasive fungal infections. Int. J. Antimicrob. Agents. 30:487-495. (Pubitemid 350051774)
28. Sokol-Anderson, M. L., J. Brajtburg, and G. Medoff. 1986. Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154:76-83. (Pubitemid 16088305)
29. Steinbach, W. J., et al. 2004. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob. Agents Chemother. 38:3217-3225. (Pubitemid 39129310)
30. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
31. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
32. Turnidge, J., and D. L. Patterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408. (Pubitemid 47175010)
33. Vanden Bossche, H., et al. 1994. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Vet. Mycol. 32:189-202.
34. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. (Pubitemid 351265310)
35. Walsh, T. J., et al. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319. (Pubitemid 36898165)